Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo/Vertex HIV protease inhibitor shows reduction in viral load.

Executive Summary

GLAXO/VERTEX HIV PROTEASE INHIBITOR 141W94 SHOWS 99% REDUCTION IN VIRAL LOAD at a dose level of 1200 mg twice daily, according to results of a Phase I/II study presented Sept. 16 at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy in New Orleans. The study also showed a median increase of 110 CD4 cells over baseline at 1200 mg b.i.d., the highest dose tested.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel